07:00 , May 18, 2015 |  BC Week In Review  |  Company News

AOP Orphan, Cardiome deal

AOP Orphan granted Cardiome rights to market IV and powder formulations of Esmocard esmolol in Italy, France, Spain and Belgium. The small molecule adrenergic receptor beta 1 ( ADRB1 ) antagonist is approved to treat...
07:00 , May 27, 2013 |  BioCentury  |  Strategy

Royalty pain or gain

Elan Corp. plc shareholders have a lot to consider before a June 17 meeting to decide the fate of the biotech. Investors can walk away after pocketing the $6.4 billion proposed by suitor Royalty Pharma...